Listen Now

Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha, Nebraska, discusses the most important lymphoma studies presented at the 2022 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASH23/Lymphoma).

Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York City discusses the management of desmoid tumors. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayDesmoidTumors22).

Dr Bob Li from Memorial Sloan Kettering Cancer Center in New York City discusses the current and future roles of targeted therapy for HER2-altered non-small cell lung cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHER2AlteredNSCLC22).

Dr Edward Garon from the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, California, discusses the management of NSCLC in patients who do not have actionable activating mutations. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNSCLCwithoutActionableMutation22).

Dr Srdan Verstovsek from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses new data with myeloproliferative neoplasms presented at the 2022 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASH23/MPN).

Dr Gilles Salles from Memorial Sloan Kettering Cancer Center in New York City discusses recent data from clinical trials evaluating targeted therapies for diffuse large B-cell lymphoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayDLBCL22).

Dr Richard Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses new data in acute myeloid leukemia and myelodysplastic syndromes presented at the 2022 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASH23/AMLMDS).

Dr Erica Mayer from the Dana-Farber Cancer Institute in Boston, Massachusetts and Dr Ruth O'Regan from the University of Rochester in Rochester, New York discuss new developments in ER-positive breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayERPositiveBreastCancer23).

Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy discusses recent therapeutic advances in HER2-positive metastatic breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHER2PositivemBC22).

Dr Manish Shah from Weill Cornell Medicine in New York City discusses current approaches to the management of upper GI malignancies and the potential future role of novel therapies for patients with these cancers.  CME information and select publications here (http://www.researchtopractice.com/OncologyTodayGastroesophageal22).

Dr Scott Tagawa from Weill Cornell Medicine Sandra and Edward Meyer Cancer Center in New York, New York discusses current treatments and management strategies for metastatic urothelial bladder cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMetastaticBladderCancer22).

Dr Thomas Herzog from the University of Cincinnati Medical Center in Cincinnati, Ohio, discusses updates and recent changes in the use of PARP inhibitors for ovarian cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayOvarianPARP22).

Dr Omid Hamid from the Angeles Clinic and Research Institute in Los Angeles, California, discusses novel immunotherapies and combination treatments for patients with metastatic melanoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNovelStrategiesMelanoma22).

Dr Eric Sherman from Memorial Sloan Kettering Cancer Center in New York City discusses recent therapeutic advances in thyroid cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayThyroid22).

Dr Jeffrey Zonder from Karmanos Cancer Institute in Detroit, Michigan discusses the biology, presentation and current management of AL amyloidosis and emerging data with novel therapies. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayALAmyloidosis22).

Dr Ruben Mesa from the Mays Cancer Center in San Antonio, Texas, discusses therapeutic advances in the management of patients with myelofibrosis. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNovelAgentsMF22).

Dr Toni Choueiri from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent therapeutic advances in the care of patients with renal cell carcinoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayRCC22).

Professor Arndt Vogel from Hannover Medical School in Germany discusses major clinical trials and recent changes in the treatment of advanced hepatocellular carcinoma. CME information and select publications [here] (http://www.researchtopractice.com/OncologyTodayHCC22)

Dr Eytan Stein from Memorial Sloan Kettering Cancer Center in New York City discusses novel agents and strategies in the treatment of acute myeloid leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNovelAgentsAML22).

Dr Amy DeZern from The Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, discusses recent therapeutic advances in higher-risk myelodysplastic syndromes. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHigherRiskMDS22).